CD19 and neoplasm: Mice bearing tumors lacking PSMA expression showed a reduced tumor burden by bioluminescence imaging compared with mice bearing CD19+/PSMA +tumors when treated with the iCARs.69 Flow cytometric analysis of the bone marrow confirmed similar proportions of dual positive tumor cells remaining in iCAR treated mice compared with the non-T cell treated control.